Overexpression in metastatic breast cancer supports Syndecan-1 as a marker of invasiveness and poor prognosis.
Brain metastases
Breast cancer
Membrane localization
Metastatic process
Syndecan-1 expression
Journal
Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
06
05
2022
accepted:
23
08
2022
medline:
29
8
2023
pubmed:
11
9
2022
entrez:
10
9
2022
Statut:
ppublish
Résumé
Metastasis is the main cause of breast cancer (BC) mortality. Increasing evidence points to a role of syndecan-1 (CD138) expression as a prognostic marker involved in BC tissue and leptomeningeal metastasis. Aim of this study was to investigate and compare syndecan-1 tissue expression and localization in primary and secondary BC, focusing on brain metastases. Syndecan-1 expression was determined by immunohistochemistry. Focal vs diffuse (< or > 50% of cancer cells, respectively) pattern of expression, cellular localization (cytoplasm vs membrane) and intensity of immunostaining on neoplastic cells were evaluated. Moreover, the extent and pattern of expression of syndecan-1 were compared between primary tumors and paired metastases and correlated with the tumor intrinsic subtype. A total of 23 cases, 10 with paired primary and metastatic tumor and 13 brain metastases, were evaluated. Syndecan-1 was expressed in both primary and metastatic BC. A diffuse cytoplasmic expression was observed in most primary BCs; by contrast, all metastatic lesions showed a membrane pattern of expression, suggesting a shift in cellular localization of syndecan-1 during the metastatic process. Concerning the extent of expression, we observed in metastatic lesions, a trend of association between intrinsic subtypes and extent of positivity. In particular, both BC characterized by overexpression of HER2 and triple-negative tumors were correlated with a diffuse pattern of expression with a moderate to strong intensity. A diffuse cytoplasmic expression was observed in most primary BCs; by contrast, all metastatic lesions showed a membrane pattern of expression, suggesting a shift in cellular localization of syndecan-1 during the metastatic process.
Sections du résumé
BACKGROUND
BACKGROUND
Metastasis is the main cause of breast cancer (BC) mortality. Increasing evidence points to a role of syndecan-1 (CD138) expression as a prognostic marker involved in BC tissue and leptomeningeal metastasis. Aim of this study was to investigate and compare syndecan-1 tissue expression and localization in primary and secondary BC, focusing on brain metastases.
METHODS
METHODS
Syndecan-1 expression was determined by immunohistochemistry. Focal vs diffuse (< or > 50% of cancer cells, respectively) pattern of expression, cellular localization (cytoplasm vs membrane) and intensity of immunostaining on neoplastic cells were evaluated. Moreover, the extent and pattern of expression of syndecan-1 were compared between primary tumors and paired metastases and correlated with the tumor intrinsic subtype.
RESULTS
RESULTS
A total of 23 cases, 10 with paired primary and metastatic tumor and 13 brain metastases, were evaluated. Syndecan-1 was expressed in both primary and metastatic BC. A diffuse cytoplasmic expression was observed in most primary BCs; by contrast, all metastatic lesions showed a membrane pattern of expression, suggesting a shift in cellular localization of syndecan-1 during the metastatic process. Concerning the extent of expression, we observed in metastatic lesions, a trend of association between intrinsic subtypes and extent of positivity. In particular, both BC characterized by overexpression of HER2 and triple-negative tumors were correlated with a diffuse pattern of expression with a moderate to strong intensity.
CONCLUSION
CONCLUSIONS
A diffuse cytoplasmic expression was observed in most primary BCs; by contrast, all metastatic lesions showed a membrane pattern of expression, suggesting a shift in cellular localization of syndecan-1 during the metastatic process.
Identifiants
pubmed: 36088392
doi: 10.1007/s10238-022-00880-7
pii: 10.1007/s10238-022-00880-7
pmc: PMC10460700
doi:
Substances chimiques
Biomarkers, Tumor
0
Syndecan-1
0
SDC1 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1641-1647Informations de copyright
© 2022. The Author(s).
Références
Nat Rev Dis Primers. 2019 Sep 23;5(1):66
pubmed: 31548545
Eur J Surg Oncol. 2019 Jul;45(7):1132-1137
pubmed: 30598194
Oncotarget. 2017 Apr 25;8(17):27990-27996
pubmed: 28427196
Mol Carcinog. 2019 Dec;58(12):2306-2315
pubmed: 31545001
Med Oncol. 2000 Nov;17(4):279-86
pubmed: 11114706
PLoS One. 2017 Sep 18;12(9):e0184680
pubmed: 28922402
Br J Cancer. 2008 Jun 17;98(12):1993-8
pubmed: 18542065
Pathol Res Pract. 2016 Jan;212(1):24-30
pubmed: 26616114
Oncotarget. 2017 Nov 30;8(67):111444-111455
pubmed: 29340066
Breast Cancer Res. 2017 Apr 11;19(1):46
pubmed: 28399903
Ann Oncol. 2011 Aug;22(8):1736-47
pubmed: 21709140
Front Biosci (Elite Ed). 2012 Jan 01;4(4):1528-41
pubmed: 22201973
Matrix Biol. 2012 Jan;31(1):3-16
pubmed: 22033227
Mol Cancer. 2017 Mar 7;16(1):57
pubmed: 28270211
Breast Cancer Res Treat. 2019 Nov;178(1):35-49
pubmed: 31327090